VivoSeq
Oncology

Pheochromocytoma

1

Pipeline Programs↗

6

Active Trials↗

1

Companies Involved↗

Pheochromocytoma is an early-stage landscape with 1 program across 1 company. The most active players are Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Belzutifan

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

14

clinical trials

Completed7 · 50%
Recruiting4 · 29%
Not yet recruiting2 · 14%
Approved for marketing1 · 7%

Clinical Trials

Trial Activity

14 trials

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
Recruiting·SSeoul National University Hospital·Phase 4·NCT05702944·24 enrolled
Diagnosis of Pheochromocytoma
Recruiting·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1·NCT00004847·3,000 enrolled
18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma
Recruiting·FFirst Affiliated Hospital of Zhejiang University·N/A·NCT06813742·80 enrolled
An Experimental Pilot Study to Investigate Changes in Catecholamine Synthesis and Metabolism in Patients With Molecularly Profiled Phaeochromocytoma and Paraganglioma Taking Belzutifan
Recruiting·CCambridge University Hospitals NHS Foundation Trust·Phase 2·NCT07680205·12 enrolled
Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06429397·22 enrolled
211At-MABG in Adults With Advanced Neuroendocrine Cancers
Not yet recruiting·UUniversity of Pennsylvania·Phase 1·NCT07661420·16 enrolled
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Completed·SSeoul National University Hospital·Phase 2·NCT01152827·33 enrolled
Preoperative Alpha Blockade for Pheochromocytoma
Completed·UUniversity of California, Los Angeles·Phase 3·NCT03176693·39 enrolled
131MIBG to Treat Malignant Pheochromocytoma
Completed·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00028106·32 enrolled
Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma
Completed·KKunwu Yan,MM·N/A·NCT05803330·95 enrolled
Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis
Completed·JJagiellonian University·N/A·NCT04557072·1,344 enrolled
Magnesium and Dexmedetomidine in Pheochromocytoma
Completed·IIstanbul University·N/A·NCT05102058·108 enrolled
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT04573816·132 enrolled
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Approved for marketing·UUniversity of California, San Francisco·N/A·NCT01377532

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)